Treatment discontinuation patterns of anti-vascular endothelial growth factor in retinal vein occlusion

CONCLUSION: Over 7.5 years, treatment was discontinued for three-quarters of RVOs. Stable disease was the most common reason for discontinuation, with nearly half (45%) of all RVOs in the cohort stable off active therapy. Better visual outcomes were achieved in BRVO than in CRVO, although both groups benefited from treatment.PMID:37669742 | DOI:10.1016/j.jcjo.2023.08.005

Source: Canadian Journal of Ophthalmology - September 5, 2023 Category: Opthalmology Authors: Amy Basilious Julie Duncan Bobbi Smuck Monali S Malvankar-Mehta Verena R Juncal Phil Hooper Tom G Sheidow Source Type: research